Armata Pharmaceuticals (ARMP) vs Molecular Partners (MOLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Armata Pharmaceuticals (ARMP) has outperformed Molecular Partners (MOLN) over the past year, gaining 21.3% versus a gain of 2.7%. Over five years, ARMP leads with a +10.4% price change compared with -80.8% for MOLN. Molecular Partners is the larger company by market cap ($145.9 million vs $141.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARMP | MOLN |
|---|---|---|
| Share price | $3.81 | $3.81 |
| Market cap | $141.66M | $145.94M |
| 1-day change | -1.04% | +0.79% |
| YTD return | -39.33% | -12.59% |
| 1-year return | +21.34% | +2.70% |
| 5-year return | +10.43% | -80.76% |
| EPS (TTM) | $-5.29 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.34 | $5.36 |
| 52-week low | $3.09 | $3.53 |
| Distance from 52-week high | -76.68% | -28.92% |
| Average volume | 212.63K | 1.20K |
| Shares outstanding | 37.18M | 38.31M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARMP has outperformed MOLN by 18.6 percentage points over the past year.
ARMP vs MOLN FAQ
Which is bigger, Armata Pharmaceuticals or Molecular Partners?
Molecular Partners (MOLN) is larger, with a market capitalization of $145.94M compared with $141.66M for Armata Pharmaceuticals (ARMP).
Which stock has performed better over the past year, ARMP or MOLN?
ARMP returned +21.34% over the past 12 months, compared with +2.70% for MOLN (price return, excluding dividends). Past performance does not predict future results.
Are Armata Pharmaceuticals and Molecular Partners in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.